Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study

被引：8

作者：

Rayson, D. ^{[1
,2
,3
]}

Lutes, S. ^{[2
,3
,4
]}

Sellon, M. ^{[2
,4
]}

Colwell, B. ^{[1
,2
,3
]}

Dorreen, M. ^{[1
,2
,3
]}

Drucker, A. ^{[1
,2
,3
]}

Jeyakumar, A. ^{[1
,2
,3
]}

Snow, S. ^{[1
,2
,3
]}

Younis, T. ^{[1
,2
,3
]}

机构：

[1] QEII Hlth Sci Ctr, Div Med Oncol, Halifax, NS, Canada

[2] Dalhousie Univ, Halifax, NS, Canada

[3] QEII Hlth Sci Ctr, Atlantic Clin Canc Res Unit, Halifax, NS, Canada

[4] QEII Hlth Sci Ctr, Sch Pharm, Halifax, NS, Canada

来源：

CURRENT ONCOLOGY | 2012年 / 19卷 / 03期

关键词：

GROWTH-FACTORS; DOCETAXEL; CYCLOPHOSPHAMIDE; RECOMMENDATIONS; TRIAL;

D O I：

10.3747/co.19.940

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E216 / E218

页数：3

共 9 条

[1] Hematopoietic growth factors: ESMO Recommendations for the application [J].

Greil, R. ;

Psenak, O. .

ANNALS OF ONCOLOGY, 2007, 18 :89-91

[2] Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer [J].

Hosmer, Wylie ;

Malin, Jennifer ;

Wong, Mitchell .

SUPPORTIVE CARE IN CANCER, 2011, 19 (03) :333-341

[3] Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer [J].

Jones, Stephen E. ;

Savin, Michael A. ;

Holmes, Frankie Ann ;

O'Shaughnessy, Joyce A. ;

Blum, Joanne L. ;

Vukelja, Svetislava ;

McIntyre, Kristi J. ;

Pippen, John E. ;

Bordelon, James H. ;

Kirby, Robert ;

Sandbach, John ;

Hyman, William J. ;

Khandelwal, Pankaj ;

Negron, Angel G. ;

Richards, Donald A. ;

Anthony, Stephen P. ;

Mennel, Robert G. ;

Boehm, Kristi A. ;

Meyer, Walter G. ;

Asmar, Lina .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (34) :5381-5387

[4]

Lyman GH, 2000, EUR J CANCER, V36, pS15

[5]

Madarnas Y, 2011, CURR ONCOL, V18, P119

[6]

Myers R, 2009, CANCER RES, V69, P2092

[7] Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial [J].

Roche, Henri ;

Fumoleau, Pierre ;

Spielmann, Marc ;

Canon, Jean-Luc ;

Delozier, Thierry ;

Serin, Daniel ;

Symann, Michel ;

Kerbrat, Pierre ;

Soulie, Patrick ;

Eichler, Francoise ;

Viens, Patrice ;

Monnier, Alain ;

Vindevoghel, Anita ;

Campone, Mario ;

Goudier, Marie-Josephe ;

Bonneterre, Jacques ;

Ferrero, Jean-Marc ;

Martin, Anne-Laure ;

Geneve, Jean ;

Asselain, Bernard .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (36) :5664-5671

[8] 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline [J].

Smith, Thomas J. ;

Khatcheressian, James ;

Lyman, Gary H. ;

Ozer, Howard ;

Armitage, James O. ;

Balducci, Lodovico ;

Bennett, Charles L. ;

Cantor, Scott B. ;

Crawford, Jeffrey ;

Cross, Scott J. ;

Demetri, George ;

Desch, Christopher E. ;

Pizzo, Philip A. ;

Schiffer, Charles A. ;

Schwartzberg, Lee ;

Somerfield, Mark R. ;

Somlo, George ;

Wade, James C. ;

Wade, James L. ;

Winn, Rodger J. ;

Wozniak, Antoinette J. ;

Wolff, Antonio C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3187-3205

[9] High Rate of Febrile Neutropenia in Patients With Operable Breast Cancer Receiving Docetaxel and Cyclophosphamide [J].

Soong, Derrick ;

Haj, Reem ;

Leung, Mova G. ;

Myers, Robert ;

Higgins, Brian ;

Myers, Jeff ;

Rajagopal, Sudha .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :E101-E102

← 1 →